TRAVERE THERAPEUTICS INC (TVTX) Stock News
NASDAQ:TVTX - Nasdaq - US89422G1076 - Common Stock - Currency: USD
TVTX Latest News, Press Relases and Analysis
Travere Therapeutics to Report First Quarter 2025 Financial Results
Travere Therapeutics price target lowered to $30 from $32 at Scotiabank
Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on the shares. The company recently presented updated data for its Filspari in IgA nephropathy and focal segmental glomerulosclerosis, reiterating the drug’s “robust clinical profile,” the analyst tells investors. While Vanrafia may out pressure on new patient starts, the firm believes Filspari’s launch should continue upward due to the drug’s differentia
Mentions: WMT
Invest Like Warren Buffett: Is This Pipeline Stock and Its 6.9% Yield Right for Your Income Portfolio?
Warren Buffett is the long-time CEO of the conglomerate Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B). One of the easiest investment ideas to glean from Berkshire's business portfolio is buying midstream stocks. What does Warren Buffett invest in?
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
/PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the conversion of...
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: VRTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.
Mentions: NVS
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
Travere announces sNDA submission to FDA based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS, a rare kidney condition....
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the...
Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50...
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024...
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug
The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug
The company is nearing a highly anticipated approval for a kidney disease drug.
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25...
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Travere Therapeutics Provides Corporate Update and 2025 Outlook
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief...